

K080147

510(k) Summary

FEB 27 2008

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250
317-521-2458

Contact Person: Kay A. Taylor

Date Prepared: January 18, 2008

Device Name Proprietary name: Elecsys proBNP II CalCheck

Common name: proBNP II CalCheck

Classification name: Single (specified) analyte controls (assayed and unassayed)

Predicate device The Elecsys proBNP II CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys ProBNP CalCheck (K020883).

Device Description The Elecsys proBNP II CalCheck is a lyophilized product consisting of NT-proBNP (1-76) amide human serum and potassium phosphate buffered matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.

Intended use For use in the verification of the calibration established by the Elecsys proBNP II reagent on the Elecsys and cobas e immunoassay analyzers.

Continued on next page

510(k) Summary, Continued

Comparison Table The table below compares Elecsys proBNP II CalCheck with the predicate device, Elecsys ProBNP CalCheck (K020883).

Characteristic	Elecsys proBNP CalCheck (Predicate)	Elecsys proBNP II CalCheck
Intended Use	For use in the verification of the calibration established by the Elecsys proBNP reagent on the indicated Elecsys and cobas e immunoassay analyzers.	For use in the verification of the calibration established by the Elecsys proBNP II reagent on the Elecsys and cobas e immunoassay analyzers.
Levels	Three	same
Format	Lyophilized	same
Handling	Reconstitute with exactly 1.0 mL distilled or deionized water and allow standing closed for 15 minutes, then mixing gently.	Reconstitute with exactly 1.0 mL distilled or deionized water and allow standing closed for 15 minutes, then mixing gently.
Stability	<u>Unopened:</u> • Store at 2-8°C until expiration date <u>Reconstituted:</u> • 20 – 25 °C : 4 hrs	same
Matrix	Level 1: NT-proBNP free human serum matrix Levels 2/3: synthetic NT-proBNP in human serum / buffer matrix	same

Performance Characteristics The Elecsys proBNP II CalCheck was evaluated for value assignment and stability.



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Roche Diagnostics
c/o Ms. Kay Taylor, (ASCP)
Regulatory Affairs Principal
9115 Hague Road
P.O. Box 50416
Indianapolis, IN 46250-0416

FEB 27 2008

Re: k080147
Trade Name: Elecsys proBNP II CalCheck
Regulation Number: 21 CFR 862.1660
Regulation Name: Quality control material (assayed and unassayed)
Regulatory Class: Class I reserved
Product Code: JJX
Dated: January 18, 2008
Received: January 22, 2008

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Jean M. Cooper, M.S., D.V.M.

Director

Division of Chemistry and Toxicology

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

Indication for Use – Elecsys proBNP II CalCheck

510(k) Number (if known): K080147

Device Name: Elecsys proBNP II CalCheck

Indication For Use:

For use in the verification of the calibration established by the Elecsys proBNP II reagent on the Elecsys and cobas e immunoassay analyzers.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers.


Prescription Use XXX
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use _____
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K080147